Previous close | 0.6000 |
Open | 0.6000 |
Bid | 0.0000 |
Ask | 2.0500 |
Strike | 40.00 |
Expiry date | 2025-01-17 |
Day's range | 0.6000 - 0.6000 |
Contract range | N/A |
Volume | |
Open interest | 2 |
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.